Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.58 |
| ▸ | KIT | P10721 | 2/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.58 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 5/20 | 0.51 |
| ▸ | NR2E1 | Q9Y466 | 4/20 | 0.41 |
| ▸ | RORA | P35398 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3736473 | 0.91 | KDR (0.59) | KDRKITRAF1LCKRET | |
| SCHEMBL3731842 | 0.91 | KDR (0.61) | KDRKITRAF1LCKRET | |
| SCHEMBL3738020 | 0.89 | KDR (0.56) | KDRKITRAF1LCKRET | |
| SCHEMBL3729869 | 0.89 | KDR (0.57) | KDRKITRAF1LCKRET | |
| SCHEMBL3742540 | 0.89 | KDR (0.56) | KDRKITRAF1LCKRET | |
| SCHEMBL3735412 | 0.89 | KDR (0.59) | KDRKITRAF1LCKRET | |
| SCHEMBL3731829 | 0.88 | KDR (0.63) | KDRKITRAF1LCKRET | |
| SCHEMBL3741456 | 0.85 | KDR (0.53) | KDRKITRAF1LCKRET | |
| SCHEMBL3742902 | 0.85 | KDR (0.53) | KDRKITRAF1LCKRET | |
| SCHEMBL3735406 | 0.85 | KDR (0.54) | KDRKITRAF1LCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111349-A1 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | claimed |
| WO-2006034111-A1 | (ARYLAMIDOARYL)SQUARAMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-7829717-B2 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829717-B2 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829717-B2 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20060111349-A1 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2006034111-A1 | (ARYLAMIDOARYL)SQUARAMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111349-A1 | (Arylamidoaryl)squaramide compounds | KIT, TSSK6, MCTS1 | KDR 1120/4885KIT 1/4885RAF1 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.